Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update — Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) o Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 o Anti
How this was made
The 30-second read
Why it matters
The disclosed trial initiation and FDA designation are primary catalysts that could move KRRO's stock.
Market read
New clinical data and regulatory progress may attract biotech investors and affect KRRO's valuation.
What to watch
Potential regulatory hurdles and competition in RNA therapeutics not fully addressed.
Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Korro initiated dosing in the Phase 1/2 ANCHOR trial and reported an extended cash runway into the second half of 2028, while collaboration revenue was zero and the company remained loss-making.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenue, three months ended September 30GAAP | $ — (in thousands) | – | – |
| Research and development, three months ended September 30GAAP | 12.10M | – | – |
| General and administrative, three months ended September 30GAAP | 6.35M | – | – |
| Restructuring charge, three months ended September 30GAAP | — (in thousands) | – | – |
| Total operating expenses, three months ended September 30GAAP | 18.46M | – | – |
| Loss from operations, three months ended September 30GAAP | −18.46M | – | – |
| Other income, net, three months ended September 30GAAP | 1.17M | – | – |
| Loss before provision for income taxes, three months ended September 30GAAP | −17.29M | – | – |
| Provision for income taxes, three months ended September 30GAAP | −260K | – | – |
| Net loss, three months ended September 30GAAP | −$17.55M | – | – |
| Unrealized loss on available-for-sale marketable securities, three months ended September 30GAAP | −131K | – | – |
| Foreign currency translation adjustments, net, three months ended September 30GAAP | 15K | – | – |
| Comprehensive loss, three months ended September 30GAAP | −$17.66M | – | – |
| Net loss per share, basic and diluted, three months ended September 30GAAP | $ (0.98 ) | – | – |
| Weighted-average shares used in computing net loss per share, basic and diluted, three months ended September 30GAAP | 17,867,091 | – | – |
| Collaboration revenue, nine months ended September 30GAAP | $ — (in thousands) | – | – |
| Research and development, nine months ended September 30GAAP | 38.64M | – | – |
| General and administrative, nine months ended September 30GAAP | 20.36M | – | – |
| Restructuring charge, nine months ended September 30GAAP | — (in thousands) | – | – |
| Total operating expenses, nine months ended September 30GAAP | 59.00M | – | – |
| Loss from operations, nine months ended September 30GAAP | −59.00M | – | – |
| Other income, net, nine months ended September 30GAAP | 3.38M | – | – |
| Loss before provision for income taxes, nine months ended September 30GAAP | −55.63M | – | – |
| Provision for income taxes, nine months ended September 30GAAP | −463K | – | – |
| Net loss, nine months ended September 30GAAP | −$56.09M | – | – |
| Unrealized loss on available-for-sale marketable securities, nine months ended September 30GAAP | −558K | – | – |
| Foreign currency translation adjustments, net, nine months ended September 30GAAP | 41K | – | – |
| Comprehensive loss, nine months ended September 30GAAP | −$56.61M | – | – |
| Net loss per share, basic and diluted, nine months ended September 30GAAP | $ (3.57 ) | – | – |
| Weighted-average shares used in computing net loss per share, basic and diluted, nine months ended September 30GAAP | 15,717,711 | – | – |
| Cash, cash equivalents and marketable securities, September 30, 2026GAAP | $124.8M | – | – |
| Working capital, September 30, 2026GAAP | 94.01M | – | – |
| Total assets, September 30, 2026GAAP | 148.1M | – | – |
| Total liabilities, September 30, 2026GAAP | 59.75M | – | – |
| Total stockholders' equity, September 30, 2026GAAP | 88.37M | – | – |
2027 anticipated milestones outlook
- NoteKRRO-121: begin dosing participants with UCDs in Part 2 of ANCHOR in the first half of 2027, subject to regulatory clearance to proceed
- NoteKRRO-121: report interim data from ANCHOR in the second half of 2027
- NoteKRRO-111: submit a regulatory application in the first half of 2027
- NoteKorro expects its cash, cash equivalents and marketable securities as of September 30, 2026 will fund operating expenses and capital expenditure requirements into the second half of 2028.
What drove it
- Korro dosed the first cohort in ANCHOR, the global Phase 1/2 clinical trial program for KRRO-121 in healthy volunteers and participants with UCD.
- The first SAD cohort received either a single 2 mg/kg dose of KRRO-121 or placebo.
- R&D expense decreased primarily due to decreases in KRRO-110 external expenses, personnel expenses and facilities expenses, partially offset by increases in KRRO-121 and KRRO-111 external expenses and other research and pre-development candidate expenses.
- Collaboration revenue decreased due to the agreed 12-month pause of the collaboration agreement with Novo Nordisk in November 2025.
- KRRO-111 repeat-dose studies in the NSG-Piz mouse model achieved >95% editing of the SERPINA1 transcripts.
Concerns
- There was no collaboration revenue for the three months ended September 30, 2026.
- Korro reported a net loss of $17.5 million for the three months ended September 30, 2026.
- Dosing participants with UCDs in Part 2 of ANCHOR is subject to regulatory clearance to proceed.
- KRRO-111 data disclosed in the release are preclinical.
What to watch
- Initiation of dosing of participants with UCDs in Part 2 of ANCHOR in the first half of 2027.
- Interim data from ANCHOR in the second half of 2027.
- The planned KRRO-111 regulatory application in the first half of 2027.
- Progress of the Novo Nordisk collaboration following the agreed 12-month pause announced in November 2025.
- Cash runway execution into the second half of 2028.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $124.8 million as of September 30, 2026, compared to $85.2 million as of December 31, 2025.
- Working capital was 94,012 (in thousands) as of September 30, 2026, compared to 70,435 (in thousands) as of December 31, 2025.
- Total assets were 148,120 (in thousands) as of September 30, 2026, compared to 113,506 (in thousands) as of December 31, 2025.
- Total liabilities were 59,746 (in thousands) as of September 30, 2026, compared to 62,067 (in thousands) as of December 31, 2025.
- Total stockholders' equity was 88,374 (in thousands) as of September 30, 2026, compared to 51,439 (in thousands) as of December 31, 2025.
Analysis
Korro's third-quarter update was led by clinical execution rather than commercial activity. The company dosed the first cohort in the ANCHOR Phase 1/2 program for KRRO-121, with participants in the first SAD cohort receiving either a single 2 mg/kg dose or placebo. The next material clinical milestones are dosing UCD participants in the first half of 2027, subject to regulatory clearance, and an interim ANCHOR data report in the second half of 2027.
Management, verbatim
Initiating dosing in ANCHOR brings KRRO-121 a meaningful step closer to these patients, and we look forward to dosing participants with UCDs in the first half of 2027.
Ram Aiyar, PhD, MBA, Chief Executive Officer and President of Korro Bio
In AATD, our preclinical data showing over 95% correction of the disease-causing transcripts gives us confidence as we prepare KRRO-111 for the clinic.
Ram Aiyar, PhD, MBA, Chief Executive Officer and President of Korro Bio
We are focused on execution, with two GalNAc-delivered RNA-editing programs advancing toward clinical data, and a cash runway into the second half of 2028.
Ram Aiyar, PhD, MBA, Chief Executive Officer and President of Korro Bio
Not in the filing
stated, not guessed- Gross profit and gross margin
- Operating cash flow
- Free cash flow
- Cash capital expenditures
- Debt balance
- Share repurchases
- Dividends
- Non-GAAP financial measures
- Financial revenue, expense, margin, or tax-rate guidance
- Prior-quarter comparative figures for the three-month income-statement metrics
- Prior-year comparative figures for September 30, 2026 balance-sheet metrics
- Reportable revenue segments
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
SEC Form 8‑K filing provides the company's quarterly financials and updates on its RNA‑editing pipeline.
Ticker impact
KRRO reported Q3 2026 financial results, initiated Phase 1/2 dosing of KRRO-121 and received FDA rare pediatric disease designation.
potential upward pressure as investors price in clinical progress and cash runway
First report of trial dosing and FDA designation provides fresh material; market typically reacts positively to such biotech milestones.
Market effects
Highlights growing interest in RNA-editing therapeutics within biotech sector.
US biotech investors may adjust exposure to early-stage RNA platforms.
Advances could influence global biotech R&D focus on RNA editing.
Counterpoint
Clinical timelines may slip, and cash runway could become constrained if expenses rise.
Key entities
- companyKorro Bio, Inc.
Clinical‑stage biopharma developing RNA‑editing medicines.
